Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma

Leukemia

Volumn 26, Issue 7, 2012, Pages 1671-1674

  Cesarman Maus, G ^a   Braggio, E ^b   Maldonado, H ^a   Fonseca, R ^b  

^a NCI   (Mexico)

^b MAYO CLINIC   (United States)

Author keywords

myeloma; thrombosis; tissue factor

Indexed keywords

THROMBOPLASTIN;

ARTICLE; BONE MARROW BIOPSY; CANCER CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; THROMBOSIS; TUMOR CELL; TUMOR MICROENVIRONMENT;

BLOOD COAGULATION; BONE MARROW; CELL LINE, TUMOR; HUMANS; IMMUNOENZYME TECHNIQUES; MULTIPLE MYELOMA; NEOPLASMS; PLASMA CELLS; PROGNOSIS; THROMBOPLASTIN; THROMBOSIS;

EID: 84863784755     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.43     Document Type: Article

References (26)

1. Levitan N, Dowlati A, Remick S, Tahsildar HI, Sivinski LD, Beyth R et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using medicare claims data. Medicine 1999; 78: 285-291.
2. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
3. Boccaccio P, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol 2009; 27: 4827-4833.
4. Zwicker JI. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008; 34: 195-198.
5. Tesselaar ME, Romijn FP, van der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5: 520-527.
6. van Marion AM, Auwerda JJ, Lisman T, Sonneveld P, de Maat MP, Lokhorst HM et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008; 32: 1078-1084.
7. Mateos V. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010; 36S2: S2-S32.
8. Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis 2007; 18: 595-598.
9. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 2010; 28: 132-135.
10. Niesvizky R, Mart́nez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007; 48: 2330-2337.
11. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144.
12. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026-1035.
13. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI et al. Oncogenic events regulate tissue factor expression in colorectalcancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105: 1734-1741.
14. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
15. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost 2006; 32: 24-32.
16. Zhang Y, Deng Y, Luther T, Müller M, Ziegler R, Waldherr R et al. Tissue factor controls the balance of angiogenic and antiangioenic properties of tumor cells in mice. J Clin Invest 2010; 94: 111320-111327.
17. Kasthuri RS, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27: 4834-4838.
18. Auwerda JJ, Yuana Y, Osanto S, de Maat MP, Sonneveld P, Bertina RM et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011; 105: 14-20.
19. Negaard HF, Iversen PO, stenstad B, Iversen N, Holme PA, Sandset PM. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost 2008; 99: 1040-1048.
20. Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27: 4848-4857.
21. Mechiche H, Cornillet-Lefebvre P, Nguyen P. A subpopulation of human B lymphocytes can express a functional tissue factor in response to phorbol myristate acetate. Thromb Haemost 2005; 94: 146-154.
22. Shimizu K, Itoh J. A possible link between Trousseau's syndrome and tissue factor producing plasma cells. Am J Hematol 2009; 84: 382-385.
23. Egorina EM, Sovershaev MA, Olsen JO, sterud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. Blood 2008; 111: 1208-1216.
24. Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D et al. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 1999; 81: 589-593.
25. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F et al. Aspirin, Warfarin, or Enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 29: 986-993.
26. Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 2010; 115: 605-614.